<DOC>
	<DOCNO>NCT01174901</DOCNO>
	<brief_summary>Headache common symptom , patient often seek medical attention emergency department due headache . The aim CoHead Study find possible measuring copeptin , marker stress blood , find patient simple headache patient dangerous headache symptom underlie disease need investigation treatment . Copeptin marker physical stress test patient stroke , heart attack pneumonia . In illness , patient serious form high level copeptin , one mild presentation affection low level copeptin . The investigator expect show patient headache .</brief_summary>
	<brief_title>Copeptin Risk Stratification Non-traumatic Headache Emergency Setting - The CoHead Study</brief_title>
	<detailed_description>Background : In emergency setting , non-traumatic headache ( NTH ) 80 % benign symptom , serious cause rule . Copeptin , surrogate marker antidiuretic hormone ( ADH ) , marker individual stress level , even subtle cortisol . As prognostic stress hormone hold promise prognostic point care tool risk stratification different acute illness acute myocardial infarction , respiratory tract infection cerebrovascular event , among others . Objective : To evaluate copeptin marker risk stratification NTH . Design : Prospective multicenter observational cohort study derivation set validation set . Location Setting : Emergency Department ( ED ) Medical Policlinic ( MUP ; walk-in clinic ) Neurologic Clinic ( NC ) University Hospital Basel . ED NC Cantonal Hospital Aarau . Intervention : Patients present ED MUP NC NTH recruit 1-year-period . After informed consent give patient , baseline data assess include medical history , clinical item ( i.e . neurological status , vital parameter , blood pressure , BMI ) routine laboratory item . Patients evaluate use validate standardized diagnostic tool questionnaire . CT scan diagnostics , lumbar puncture , MRI , etc. , order upon request treat physician . All diagnostic procedure , result , diagnosis make treat physician initiate therapy record . Copeptin measure admission batch analysis blind laboratory staff upon completion study . After 3 month , patient followed-up structure telephone interview ass final diagnosis outcome ( i.e . MIDAS-Questionnaire ) . The final diagnosis make two independent physician accord ICHDII-criteria verified board-certified neurologist , blind copeptin level . Thereby , primary secondary headache entity classify accord ICHD . Endpoints : The primary endpoint study serious secondary NTH oppose benign , self-limiting NTH . Serious secondary NTH define composite endpoint include different secondary NTH cause entity list International Classification Headache Disorders ( ICHD ) -II-Criteria . The secondary endpoint clinical outcome patient ; thereby look all-cause mortality within 3-month follow-up period morbidity measure MIDAS-questionnaire . Study hypothesis : We hypothesize copeptin serve point care tool discriminate benign headache potentially serious secondary headache ( e.g . subarachnoidal hemorrhage ( SAH ) cerebral aneurysm , intracranial bleeding ( ICB ) , brain tumor , vasculitis , meningitis ) require prompt hospitalisation intervention . Based copeptin value measure acute disease , assume critical range 5 20 pmol/l . The low copeptin cutoff point ≤ 5 pmol/l sensitivity ≥ 97 % rule serious secondary headache , high cutoff point ≥ 20 pmol/l specificity 90 % confirm serious NTH . Analysis : Based data two previous year , aim recruit 600 - 800 patient within one year sit Basel Aarau , respectively , 10-20 % present serious secondary NTH . We calculate 95 % confidence interval sensitivity copeptin &lt; 10 % perform multivariable logistic regression analysis ass independent additive utility copeptin compare risk score outcome predictor . The first 50 % patient used derivation set second 50 % validation set , base timely inclusion patient . Significance : If copeptin biomarker safely rule serious secondary cause NTH , represent tool optimize allocation health care resource .</detailed_description>
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Headache</mesh_term>
	<criteria>headache time screen Patients must able give informed consent le 18 year age preceding ( head ) trauma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>cephalalgia</keyword>
	<keyword>copeptins</keyword>
	<keyword>biomarkers</keyword>
	<keyword>headache</keyword>
	<keyword>C-terminal provasopression</keyword>
	<keyword>physiological stress response</keyword>
</DOC>